Population
Patients with cardiovascular disease receiving antiplatelet therapy
Design
Review
Authors
Loading...
Supports pharmacogenetic contributions to antiplatelet variability; leaves open whether genotyping improves outcomes.
Genetic polymorphisms in various receptors and enzymes contribute to individual variability in response to aspirin and clopidogrel, potentially explaining recurrent atherothrombotic events despite adequate therapy.
Fehér et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: